Abstract: Exemplary embodiments provide systems and methods for portable medical ultrasound imaging. Preferred embodiments utilize a tablet touchscreen display operative to control imaging and display operations without the need for using traditional keyboards or controls. Certain embodiments provide ultrasound imaging system in which the scan head includes a beamformer circuit that performs far field sub array beamforming or includes a sparse array selecting circuit that actuates selected elements. Exemplary embodiments also provide an ultrasound engine circuit board including one or more multi-chip modules, and a portable medical ultrasound imaging system including an ultrasound engine circuit board with one or more multi-chip modules. Exemplary embodiments also provide methods for using a hierarchical two-stage or three-stage beamforming system, three dimensional ultrasound images which can be generated in real-time.

Abstract: A non-leaching mediator may include a polymer having a polymeric backbone, and a plurality of phenothiazine groups bonded to the polymeric backbone. The plurality of phenothiazine groups may include at least one of a phenothiazine group having the general formula (IV): and salts thereof, where n is about 9 and “R” represents the polymeric backbone to which the phenothiazine group is bonded, and a phenothiazine group having the general formula (V): and salts thereof, where n is about 9 and “R” represents the polymeric backbone to which the phenothiazine group is bonded.

Abstract: A non-leaching mediator may include a polymer having a polymeric backbone, and a plurality of phenothiazine groups bonded to the polymeric backbone. The plurality of phenothiazine groups may include at least one of a phenothiazine group having the general formula (IV): and salts thereof, where n is about 9 and “R” represents the polymeric backbone to which the phenothiazine group is bonded, and a phenothiazine group having the general formula (V): and salts thereof, where n is about 9 and “R” represents the polymeric backbone to which the phenothiazine group is bonded.

Abstract: A non-leaching mediator may include a polymer having a polymeric backbone, and a plurality of phenothiazine groups bonded to the polymeric backbone. The plurality of phenothiazine groups may include at least one of a phenothiazine group having the general formula (IV): and salts thereof, where n is about 9 and “R” represents the polymeric backbone to which the phenothiazine group is bonded, and a phenothiazine group having the general formula (V): and salts thereof, where n is about 9 and “R” represents the polymeric backbone to which the phenothiazine group is bonded.

Abstract: A non-leaching mediator may include a polymer having a polymeric backbone, and a plurality of phenothiazine groups bonded to the polymeric backbone. The plurality of phenothiazine groups may include at least one of a phenothiazine group having the general formula (IV): and salts thereof, where n is about 9 and “R” represents the polymeric backbone to which the phenothiazine group is bonded, and a phenothiazine group having the general formula (V): and salts thereof, where n is about 9 and “R” represents the polymeric backbone to which the phenothiazine group is bonded.

Abstract: A non-leaching mediator may include a polymer having a polymeric backbone, and a plurality of phenothiazine groups bonded to the polymeric backbone. The plurality of phenothiazine groups may include at least one of a phenothiazine group having the general formula (IV): and salts thereof, where n is about 9 and “R” represents the polymeric backbone to which the phenothiazine group is bonded, and a phenothiazine group having the general formula (V): and salts thereof, where n is about 9 and “R” represents the polymeric backbone to which the phenothiazine group is bonded.

Abstract: A non-leaching mediator may include a polymer having a polymeric backbone, and a plurality of phenothiazine groups bonded to the polymeric backbone. The plurality of phenothiazine groups may include at least one of a phenothiazine group having the general formula (IV): and salts thereof, where n is about 9 and “R” represents the polymeric backbone to which the phenothiazine group is bonded, and a phenothiazine group having the general formula (V): and salts thereof, where n is about 9 and “R” represents the polymeric backbone to which the phenothiazine group is bonded.

Abstract: A non-leaching mediator may include a polymer having a polymeric backbone, and a plurality of phenothiazine groups bonded to the polymeric backbone. The plurality of phenothiazine groups may include at least one of a phenothiazine group having the general formula (IV): and salts thereof, where n is about 9 and “R” represents the polymeric backbone to which the phenothiazine group is bonded, and a phenothiazine group having the general formula (V): and salts thereof, where n is about 9 and “R” represents the polymeric backbone to which the phenothiazine group is bonded.

Abstract: A non-leaching mediator may include a polymer having a polymeric backbone, and a plurality of phenothiazine groups bonded to the polymeric backbone. The plurality of phenothiazine groups may include at least one of a phenothiazine group having the general formula (IV): and salts thereof, where n is about 9 and “R” represents the polymeric backbone to which the phenothiazine group is bonded, and a phenothiazine group having the general formula (V): and salts thereof, where n is about 9 and “R” represents the polymeric backbone to which the phenothiazine group is bonded.

Abstract: A non-leaching mediator may include a polymer comprising the general formula (VIII): and salts thereof, where R? is an organic group, m is 0 or 1, n is about 9, and x and y independently are an integer from 1 to 10,000.

Abstract: A non-leaching mediator may include a polymer comprising the general formula (VIII): and salts thereof, where R? is an organic group, m is 0 or 1, n is about 9, and x and y independently are an integer from 1 to 10,000.

Abstract: A non-leaching mediator may include a polymer having a polymeric backbone, and a plurality of phenothiazine groups bonded to the polymeric backbone. The plurality of phenothiazine groups may include at least one of a phenothiazine group having the general formula (IV): and salts thereof, where n is about 9 and “R” represents the polymeric backbone to which the phenothiazine group is bonded, and a phenothiazine group having the general formula (V): and salts thereof, where n is about 9 and “R” represents the polymeric backbone to which the phenothiazine group is bonded.

Abstract: A non-leaching mediator may include a compound having the general formula (I): and salts thereof, where n is about 9, and X is a halogen; a compound having the general formula (II): and salts thereof, where n is about 9, and X is a halogen; and/or a compound, having the general formula (III): and salts thereof, where n is about 8, and X is a halogen.

Abstract: A non-leaching mediator may include a polymer having a polymeric backbone, and a plurality of phenothiazine groups bonded to the polymeric backbone. The plurality of phenothiazine groups may include at least one of a phenothiazine group having the general formula (IV): and salts thereof, where n is about 9 and “R” represents the polymeric backbone to which the phenothiazine group is bonded, and a phenothiazine group having the general formula (V): and salts thereof, where n is about 9 and “R” represents the polymeric backbone to which the phenothiazine group is bonded.

Abstract: A non-leaching mediator may include a compound having the general formula (I): and salts thereof, where n is about 9, and X is a halogen; a compound having the general formula (II): and salts thereof, where n is about 9, and X is a halogen; and/or a compound, having the general formula (III): and salts thereof, where n is about 8, and X is a halogen.

Abstract: A method implemented in the form of a computer simulation code for evaluating the free energy of binding between polypeptide amino acid residues and one or more molecular fragment types is presented. The basis of the method is a novel weighted Metropolis Monte Carlo approach for sampling the grand canonical ensemble. By making use of the properties of the grand canonical ensemble, the affinity of fragments for binding in the vicinity of each protein residue can be efficiently computed. The binding volume associated to each fragment-residue pair is estimated on the basis of a simple proximity criteria, and a useful affinity mapping of the protein surface can be obtained in this way. The analysis of such data for various fragment types provides valuable information to help identify protein binding sites, as well as to identify key fragments used for building potential drug leads.

Abstract: Methods and systems of analyzing positions and orientations of molecular fragments to generate macromolecular binding ligands, including analyzing the positions and orientations of molecular fragments in relation to other molecular fragments to bond the molecular fragments to form ligands.

Abstract: An image scanner includes a main body, an optical module, a switch, a trigger member and a cover. The main body has a window for supporting a document. The optical module is used for scanning the document. The switch is used for actuating the optical module to scan the document. The cover is movably connected to the main body. The trigger member is provided on the main body or the cover for turning on the switch so as to actuate the optical module when the cover is closed to cover the window.

Abstract: Surface-crosslinked superabsorbent polymer (SAP) particles having a clay in the vicinity of the surfaces of the SAP particles a clay are disclosed. The clay is added to SAP particles during surface crosslinking to substantially reduce the generation, and recycling, of SAP fines, and to provide SAP particles having an improved acquisition rate of fluids and an improved permeability of a fluid through the swollen SAP particles. Diaper cores and absorbent articles containing the surface crosslinked SAP particles also are disclosed.

Abstract: Superabsorbent polymer (SAP) particels containing a clay are disclosed. The clay is added to an SAP hydrogel prior to SAP neutralization to provide particles having improved fluid acquisition rates and an improved permeability of a fluid through the swollen SAP-clay particles. Diaper cores and absorbent articles containing the SAP-clay particles also are disclosed.